Tebentafusp in first-line melanoma trials: An outperforming outlier

Timothée Olivier a,b,⇑, Vinay Prasad b

a Department of Oncology, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, Geneva 1205, Switzerland
b Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158, USA

A B S T R A C T

Uveal melanoma is distinct from other melanomas. In the advanced and metastatic stages, little to no improvement have been seen over time. Tebentafusp is a novel mechanism of action bispecific gp100 peptide-HLA-directed CD3 T-cell engager fusion protein (‘‘fusp’’). Tebentafusp was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The approval was based on the overall survival advantage of tebentafusp over physician’s choice therapy, in previously untreated uveal melanoma patients, based on the IMCgp100-202 trial. While we welcome positive results for this unmet need, three issues are raised by the trial. First, the control arm was restricted, precluding important options. Second, post-progression treatment was provided to a smaller fraction of patients than in real-life, which raises the question of whether overall survival was negatively impacted by limited care after the trial ended. Finally, the discrepancy between overall survival and progression-free survival benefit is an outlier in the context of previous melanoma trials. While it is clear that tebentafusp has an important role to play in this tumor type, the exact line is not yet well known. Confirmatory trials are needed for this compound.

Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T-cell engager, that was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. After early stages development [1,2], the approval was based on the overall survival (OS) advantage of tebentafusp over physician’s choice therapy, in previously untreated uveal melanoma patients, based on the IMCgp100-202, open-label, randomized, phase 3 trial (NCT03070392) [3].

Tebentafusp is a compound from a new class of reagents, called ImmTACS, for ‘‘immune-mobilizing monoclonal TCRs against cancer (ImmTACs)’’ [4]. Tebentafusp is a fusion protein (‘‘fusp’’) made of two parts. One side is a soluble affinity-enhanced T-cell receptor, targeting the gp100 protein, and the other is an anti-CD3 effector (activating anti-tumoral T cell response). Gp100 is expressed by melanoma cells, and the affinity of the T-cell receptor part of tebentafusp is restricted to gp100-HLA-A*02:01 complex recognition. When tebentafusp is attached to its HLA complex, this triggers anti-tumoral immunity through activation and recruitment of T lymphocytes (schematic illustration in Fig. 1) [5].

Consequently, patients must have HLA-A*02:01 genotype positivity, which prevalence vary according to ethnicity. In a US cohort, HLA-A2 was found in in 35% of African-Americans and 50% of Caucasian. In those subjects, the subtype HLA-A*02:01 represented most of them, again with variation across ethnic groups (53% for Asian/Pacific Islander up to 96% in Caucasian) [6].

Uveal melanoma has a different biology than other melanomas, with almost no patients presenting tumoral BRAF activating mutation. The most common driver mutations are coding for the G proteins GNAQ and GNA11 [7]. Uveal melanoma, when progressing, preferentially metastasize to the liver, most probably due to specific molecular pathways [8]. In the advanced and metastatic stages, little to no improvement have been seen over decades, with median overall survival stagnating between 6 and 10 months over time [9]. Uveal melanoma present poorer response to checkpoint inhibitors as compared to cutaneous melanoma. This may be explained by a different tumor micro-environment (low CD8 T lymphocytes and PD-L1 expression by tumor cells), yet immunotherapy strategies remain utilized and have demonstrated anti-tumoral activity in patients with uveal melanoma. Most treatment guidelines and strategies mirror those of cutaneous melanoma, although some recent trials have deliberately excluded uveal melanoma.

The IMCgp100-202 trial found an overall survival advantage of tebentafusp over physician’s choice therapy. All 378 patients that were randomly assigned had metastatic uveal melanoma; stage at diagnosis was stage I in 16% of patient, stage II in 34%, stage III in 24%, stage IV in 8% (and missing in 18%). The experimental arm achieved 21.7 months median OS as compared to 16 months, a difference of 5.6 months (hazard ratio, HR=0.51; 95% CI 0.37 to 0.71; P<0.001). Progression-free survival (PFS) was also longer in tebentafusp treated patients with 3.3 months median PFS, compared to 2.9 median PFS in the control arm, a difference of 0.4 months (HR=0.73; 95% CI, 0.58 to 0.94; P=0.01).

Tebentafusp is administered on a weekly basis, intravenously.

⇑ Corresponding author at: Department of Oncology, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, Geneva 1205, Switzerland.
E-mail address: timothee.olivier@hcuge.ch (T. Olivier).

https://doi.org/10.1016/j.tranon.2022.101408
Received 27 February 2022; Received in revised form 20 March 2022; Accepted 22 March 2022
1936-5233/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Toxicity may be reduced by progressive dose-escalation: tebentafusp was initiated at 20 μg, followed after eight days by 30 μg, and followed after one more week by 68 μg, before continuing on a weekly schedule. Tebentafusp led to cytokine release syndrome of any grade in 89% of patients (but of grade 3 or more in 1%). Other toxicities were mainly rash (83%, 18% of grade ≥ 3), pyrexia (76%, 4% of grade ≥ 3) pruritus (69%), chills (47%), nausea (43%) and fatigue (41%). Interestingly, most adverse events occurred during the first 4 weeks of dose-escalation, and decreased after this period. Adverse events leading to treatment discontinuation occurred in 2% of patients, with no treatment-reported deaths.

While we welcome positive results for this unmet need, there are three issues worth noting. First, the control arm was restricted, precluding important options. Second, post-progression treatment was provided to a smaller fraction of patients than in real-life, which raises the question of whether overall survival is negatively impacted by limited care after the trial ended. Finally, the discrepancy between OS and PFS benefit is an outlier in the context of previous melanoma trials.

First, the “investigator’s choice” control arm was restricted to three options: single-agent pembrolizumab, single-agent ipilimumab, or dacarbazine. Pembrolizumab is an anti-PD1 monoclonal antibody, ipilimumab an anti-CL4A monoclonal antibody: both are also known as “immune checkpoint inhibitors”. Dacarbazine is a cytotoxic chemotherapeutic agent, classified as an alkylating agent. A restricted “investigator’s choice” is common in industry sponsored trials, and often blocks an important standard-of-care option [10]. This restriction may create substandard control arms and favor investigational compounds.

In a retrospective study from Denmark, conducted in the immuno-therapy era, most first-line patients with uveal melanoma were treated with checkpoint inhibitors, with 22% receiving ipilimumab in combination with nivolumab: yet, this combination was not allowed in the IMCgp100-202 trial. The dual checkpoint combination (ipilimumab plus nivolumab) has been studied both retrospectively and prospectively in uveal melanoma patients [11]. In a single arm phase 2 trial, the combination led to 11.5% overall response rate (ORR) with 12.7 months median OS. In contrast, the ORR with tebentafusp was 9%, and 5% in the control arm.

Second, 43% of the IMCgp100-202 trial patients received a subsequent systemic therapy; lower than in real-life settings: this may reflect a poor access to disease modifying therapies in a trial conducted globally. In a retrospective analysis from a nationwide database conducted in Denmark, 54% of first-line treated patients received a second line treatment [12]. Interestingly, the subgroup analysis of IMCgp100-202 showed no benefit from tebentafusp in patients treated with ipilimumab in the control arm, suggesting that ipilimumab, at some point of the treatment course, may play an important role. Among control arm patients treated with pembrolizumab and receiving subsequent therapy, 72% were treated with another checkpoint inhibitor. We would have expected this rate to be higher, bearing in mind that other than ipilimumab-based options (alone or in combination) are very limited at progression.

Third, the overall survival (OS) benefit is far larger than, and disproportionate to the PFS benefit in terms of hazard ratios (HR). When the added time of median PFS was 0.4 months in patients receiving tebentafusp, the added length in median OS was 5.7 months. This was also seen in a subgroup analysis demonstrating a significant improvement in median OS among patients without disease control according to RECIST v1.1 (6.5 in the control arm vs. 15.3 months with tebentafusp (HR 0.43, 95% CI 0.27–0.68)). Also, the ORRs were poor in both arm (9% with tebentafusp, 5% in the control arm). Previously, checkpoint inhibitors demonstrated less correlation between ORR and OS than conventional chemotherapy [13]. We compare this trial to others, mathematically confirming that tebentafusp is an outlier across trials in melanoma, with an OS benefit far outweighing the PFS benefit (Fig. 2) and the ORR advantage (Fig. 3).

Tebentafusp has been heralded as an advance in this unique and neglected subtype of melanoma, and, indeed, we hope it is. Yet, overall survival gains far outstrip the PFS advance. Use of subsequent therapies is less than even real-world settings, and the control arm notably precluded treatment with ipilimumab plus nivolumab, the most active regimen, whose overall response rate surpasses the investigational arm. While it is clear that tebentafusp has an important role to play in this tumor type, the exact line is not yet well known. Confirmatory trials are needed for this compound.

**Fig. 1. Schematic Diagram Illustrating The Mechanism of Action of Tebentafusp.**

---

- **Cytokine Release, T-Cell Activation**
- **T lymphocyte**
- **Anti-CD3 effector domain**
- **HLA-A2 restricted engineered T-Cell Receptor (TCR) domain**
- **Tebentafusp (ImmTAC*)**
- **HLA-A2 gp100 melanoma cell**
- **EFICACY anti-tumor immunity recruitment activation**
- **TOXICITY cytokine release syndrome, rash, pyrexia, pruritus**

*ImmTAC: immune-mobilizing monoclonal TCRs against cancer*
Funding
This project was funded by Arnold Ventures, LLC through a grant paid to the University of California, San Francisco.

CRediT authorship contribution statement
Timothée Olivier: Conceptualization, Writing – original draft, Writing – review & editing. Vinay Prasad: Conceptualization, Writing – review & editing.

Declaration of Competing Interest
Vinay Prasad’s Disclosures: Research funding: Arnold Ventures; Royalties: Johns Hopkins Press, Medscape; Honoraria: Grand Rounds/lectures from universities, medical centers, non-profits, and professional societies; Consulting: UnitedHealthcare; Speaking fees: Evicore; Other: Plenary Session podcast has Patreon backers. Timothée Olivier have no financial nor non-financial conflicts of interest to report.

Fig. 2. Hazard Ratios (HR) For Overall Survival (OS) And Progression-free-survival (PFS) In Selected Randomized Trials In First-Line Advanced Or Metastatic Melanoma.

Fig. 3. Hazard Ratio (HR) For Overall Survival (OS) and Response Rates Differences In Selected Randomized Trials In First-Line Advanced Or Metastatic Melanoma.

References
[1] M.R. Middleton, C. McAlpine, V.K. Woodcock, et al., Tebentafusp, A TCR/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma, Clin. Cancer Res. 26 (22) (2020) 5869–5878, https://doi.org/10.1158/1078-0432.CCR-20-1247.
[2] J.J. Sacco, R.D. Carvajal, M.O. Butler, A.N. Shoukhetari, J.C. Hassel, 64MO-A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM), Ann. Oncol. 31 (7) (2020) S1441–S1451. Suppl, https://oncologypro.esmo.org/meeting-resources/esmo-immuno-oncology-virtual-congress-2020/a-phase-ph-ii-multi-center-study-of-the-safety-and-efficacy-of-tebentafusp-tebe-imcgp100-in-patients-pts-with-metastatic-uveal-melanoma-mum.
[3] P. Nathan, J.C. Hassel, P. Rutkowski, et al., Overall survival benefit with tebentafusp in metastatic uveal melanoma, N. Engl. J. Med. 385 (13) (2021) 1196–1206, https://doi.org/10.1056/NEJMoa2103485.
[4] N. Liddy, G. Bossi, K.J. Adams, et al., Monoclonal TCR-redirected tumor cell killing, Nat. Med. 18 (6) (2012) 980–987, https://doi.org/10.1038/nm.2764.
[5] G. Bossi, S. Buisson, J. Oates, B.K. Jakobsen, N.J. Hassan, ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells, Cancer Immunol. Immunother. 63 (5) (2014) 437–448, https://doi.org/10.1007/s00262-014-1525-z.
[6] J.M. Ellis, V. Henson, R. Slack, J. Ng, R.J. Hartzman, C. Katovich Hurley, Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231, Hum. Immunol. 61 (3) (2000) 334–340, https://doi.org/10.1016/s0198-8859(99)00155-x.
[7] C. Chattopadhyay, D.W. Kim, D.S. Gombos, et al., Uveal melanoma: from diagnosis to treatment and the science in between, Cancer 122 (15) (2016) 2299–2312, https://doi.org/10.1002/cncr.29727.

[8] P. Tsantoulis, M. Delorenzi, I. Biche, et al., Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma, Sci. Rep. 9 (1) (2019) 17178, https://doi.org/10.1038/s41598-019-52841-y.

[9] C. Rodriguez-Vidal, D. Fernandez-Diaz, B. Fernandez-Marta, et al., Treatment of metastatic uveal melanoma: systematic review, Cancers 12 (9) (2020) 2557, https://doi.org/10.3390/cancers12092557.

[10] T. Olivier, A. Haslam, V. Prasad, Reporting of physicians’ or investigators’ choice of treatment in oncology randomized clinical trials, JAMA Netw. Open 5 (1) (2022), e2144770, https://doi.org/10.1001/jamanetworkopen.2021.44770.

[11] J.M. Piulats, E. Espinosa, C. de la, L. Merino, et al., Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402), JCO 39 (6) (2021) 586–598, https://doi.org/10.1200/JCO.20.00550.

[12] K.F. Bol, E. Ellebaek, L. Hoejberg, et al., Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma, Cancers 11 (10) (2019) 1489, https://doi.org/10.3390/cancers11101489.

[13] G. Roviello, F. Andre, S. Venturini, et al., Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies, Eur. J. Cancer 86 (2017) 257–265, https://doi.org/10.1016/j.ejca.2017.09.018.